Javascript must be enabled to continue!
Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
View through CrossRef
Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation. We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery. Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one). Single doses of zolpidem ranged between 2.5 and 10 mg, while daily dosages ranged from 10 to 30 mg. The zolpidem dose prescribed was 5–10 mg, with single and daily doses of 7 ± 2.9 and 14.5 ± 6.0 mg, respectively. With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.1 ± 6.7 to 3.7 ± 2.5 (50.6% improvement, p < 0.0001). Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively. No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale. Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2–3 h. Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively. Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited.
Title: Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
Description:
Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment.
Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation.
We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery.
Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one).
Single doses of zolpidem ranged between 2.
5 and 10 mg, while daily dosages ranged from 10 to 30 mg.
The zolpidem dose prescribed was 5–10 mg, with single and daily doses of 7 ± 2.
9 and 14.
5 ± 6.
0 mg, respectively.
With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.
1 ± 6.
7 to 3.
7 ± 2.
5 (50.
6% improvement, p < 0.
0001).
Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively.
No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale.
Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2–3 h.
Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively.
Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited.
Related Results
Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea
Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea
AbstractObjectivesTo investigate the association between zolpidem prescription and suicide attempts in people with depressionMethodsA nationwide, population-based electronic medica...
O uso do Zolpidem no período da pandemia do COVID-19: uma revisão narrativa
O uso do Zolpidem no período da pandemia do COVID-19: uma revisão narrativa
A Organização Mundial da Saúde (OMS), em 30 de janeiro de 2020, declarou que o surto do novo coronavírus constituía uma Emergência de Saúde Pública de Importância Internacional (ES...
Comparative Efficacy of Zolpidem and Nigella Sativa in Treatment of Sleep Disorder and Vasomotor Symptoms in Menopausal Women of Women’s General Hospital
Comparative Efficacy of Zolpidem and Nigella Sativa in Treatment of Sleep Disorder and Vasomotor Symptoms in Menopausal Women of Women’s General Hospital
Objective: To evaluate the efficacy of Zolpidem and Nigella sativa compared to placebo in treatment of sleep disturbance in healthy postmenopausal women. Menopause is a period that...
Clinical Presentation and Evolution of Isolated Focal and Segmental Dystonia in Adults – 20 Years’ Experience from a Botulinum Toxin Clinic
Clinical Presentation and Evolution of Isolated Focal and Segmental Dystonia in Adults – 20 Years’ Experience from a Botulinum Toxin Clinic
Background and Objectives:
Isolated dystonia generally occurs due to genetic causes, and the pattern and distribution may change over time. Botulinum toxin is t...
Physician Approaches to the Pharmacologic Treatment of Dystonia in Cerebral Palsy
Physician Approaches to the Pharmacologic Treatment of Dystonia in Cerebral Palsy
Abstract
Objective
To determine how physicians approach pharmacologic dystonia treatment in people with CP and assess physician...
Impact de l’ordonnance sécurisée sur la prescription du zolpidem
Impact de l’ordonnance sécurisée sur la prescription du zolpidem
Introduction : en avril 2017, le zolpidem a subi un changement de réglementation obligeant sa prescription sur ordonnance sécurisée. Cette mesure est la conséquence d’une surconsom...
Rare Variant Burden in Known Dystonia Genes in Population Controls and Sporadic Dystonia Patients
Rare Variant Burden in Known Dystonia Genes in Population Controls and Sporadic Dystonia Patients
Abstract
Background
Rare mutations in genes associated with Mendelian forms of disease are a potential mechanism for sporadic d...
Zolpidem: a masked hero. A reply to ZORRO study
Zolpidem: a masked hero. A reply to ZORRO study
The use of zolpidem has been driven by the still-widespread false belief
among doctors that, since zolpidem is chemically not a benzodiazepine,
it cannot lead to addiction and tole...

